PPARA and obesity disorder: The advantage of dual PPARα/δ agonist with respect to renal function was demonstrated by a lower risk of serum creatinine elevation with elafibranor (PPARα/δ agonist) user than fenofibrate (PPARα agonist, 7.1% versus 17.2%) user with obesity and steatohepatitis [12].